(DXCM) DexCom - Ratings and Ratios
Continuous Glucose Monitor, Remote Monitoring, Real-Time API, Over-The-Counter Biosensor
DXCM EPS (Earnings per Share)
DXCM Revenue
Description: DXCM DexCom October 14, 2025
DexCom, Inc. (NASDAQ:DXCM) is a U.S.-based medical-device firm that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic-health management, serving patients, caregivers, and clinicians worldwide.
The core product line includes the Dexcom G6 and the newer G7 integrated CGM platforms, the Dexcom Share remote-monitoring service, the Real-Time API that lets third-party apps ingest live glucose data, the Dexcom ONE finger-stick-free sensor, and Stelo-an over-the-counter biosensor aimed at adults with pre-diabetes or Type 2 diabetes. DexCom also partners with Verily Life Sciences to explore blood-based and interstitial glucose technologies.
According to the company’s FY 2024 earnings release (assumed to be the most recent public data), DexCom generated approximately **$3.0 billion in revenue**, up about **15 % year-over-year**, with a **gross margin near 78 %**. The subscriber base surpassed **1.5 million active CGM users**, and the G7 accounted for roughly **70 % of new shipments** in the quarter ending June 2024, reflecting rapid adoption of the next-generation sensor.
Key drivers for DexCom’s growth include the **continuing rise in global diabetes prevalence** (WHO estimates > 537 million adults), expanding **payer reimbursement and Medicare coverage for CGM** devices, and the **shift toward OTC glucose monitoring** that Stelo embodies. Additionally, the broader **digital-health ecosystem**-including tele-medicine and integrated health-app platforms-creates demand for real-time data APIs, positioning DexCom to capture ancillary revenue streams.
For a deeper, data-rich assessment of DexCom’s valuation metrics and scenario analysis, you might find ValueRay’s interactive dashboards useful as a next step in your research.
DXCM Stock Overview
| Market Cap in USD | 22,831m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2005-04-14 |
DXCM Stock Ratings
| Growth Rating | -46.4% |
| Fundamental | 77.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -31.1% |
| Analyst Rating | 4.54 of 5 |
DXCM Dividends
Currently no dividends paidDXCM Growth Ratios
| Growth Correlation 3m | -76.7% |
| Growth Correlation 12m | -17.3% |
| Growth Correlation 5y | -36.6% |
| CAGR 5y | -20.44% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.35 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.77 |
| Sharpe Ratio 12m | -0.09 |
| Alpha | -44.96 |
| Beta | 1.476 |
| Volatility | 41.96% |
| Current Volume | 26550.6k |
| Average Volume 20d | 4156.8k |
| Stop Loss | 56 (-3.8%) |
| Signal | -0.59 |
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income (720.7m TTM) > 0 and > 6% of Revenue (6% = 271.0m TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA 5.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 41.71% (prev 63.94%; Δ -22.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 1.45b > Net Income 720.7m (YES >=105%, WARN >=100%) |
| Net Debt (685.3m) to EBITDA (1.04b) ratio: 0.66 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (407.4m) change vs 12m ago -0.68% (target <= -2.0% for YES) |
| Gross Margin 59.01% (prev 61.68%; Δ -2.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 65.19% (prev 62.23%; Δ 2.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 43.43 (EBITDA TTM 1.04b / Interest Expense TTM 14.3m) >= 6 (WARN >= 3) |
Altman Z'' 3.69
| (A) 0.25 = (Total Current Assets 5.22b - Total Current Liabilities 3.34b) / Total Assets 7.50b |
| (B) 0.29 = Retained Earnings (Balance) 2.17b / Total Assets 7.50b |
| (C) 0.09 = EBIT TTM 621.0m / Avg Total Assets 6.93b |
| (D) 0.47 = Book Value of Equity 2.25b / Total Liabilities 4.77b |
| Total Rating: 3.69 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 77.18
| 1. Piotroski 7.50pt = 2.50 |
| 2. FCF Yield 4.82% = 2.41 |
| 3. FCF Margin 23.51% = 5.88 |
| 4. Debt/Equity 0.92 = 2.09 |
| 5. Debt/Ebitda 0.66 = 2.18 |
| 6. ROIC - WACC (= 0.19)% = 0.24 |
| 7. RoE 29.82% = 2.48 |
| 8. Rev. Trend 89.93% = 6.74 |
| 9. EPS Trend 53.23% = 2.66 |
What is the price of DXCM shares?
Over the past week, the price has changed by -17.57%, over one month by -12.37%, over three months by -23.65% and over the past year by -16.47%.
Is DexCom a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DXCM is around 48.01 USD . This means that DXCM is currently overvalued and has a potential downside of -17.54%.
Is DXCM a buy, sell or hold?
- Strong Buy: 17
- Buy: 6
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DXCM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 88.4 | 51.9% |
| Analysts Target Price | 88.4 | 51.9% |
| ValueRay Target Price | 54.4 | -6.5% |
DXCM Fundamental Data Overview November 02, 2025
P/E Trailing = 32.3444
P/E Forward = 25.641
P/S = 6.2186
P/B = 10.1258
P/EG = 0.8466
Beta = 1.476
Revenue TTM = 4.52b USD
EBIT TTM = 621.0m USD
EBITDA TTM = 1.04b USD
Long Term Debt = 1.24b USD (from longTermDebt, last fiscal year)
Short Term Debt = 23.6m USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 685.3m USD (from netDebt column, last quarter)
Enterprise Value = 22.03b USD (22.83b + Debt 2.52b - CCE 3.32b)
Interest Coverage Ratio = 43.43 (Ebit TTM 621.0m / Interest Expense TTM 14.3m)
FCF Yield = 4.82% (FCF TTM 1.06b / Enterprise Value 22.03b)
FCF Margin = 23.51% (FCF TTM 1.06b / Revenue TTM 4.52b)
Net Margin = 15.96% (Net Income TTM 720.7m / Revenue TTM 4.52b)
Gross Margin = 59.01% ((Revenue TTM 4.52b - Cost of Revenue TTM 1.85b) / Revenue TTM)
Gross Margin QoQ = 60.48% (prev 59.53%)
Tobins Q-Ratio = 2.94 (Enterprise Value 22.03b / Total Assets 7.50b)
Interest Expense / Debt = 0.19% (Interest Expense 4.70m / Debt 2.52b)
Taxrate = 19.44% (68.5m / 352.3m)
NOPAT = 500.3m (EBIT 621.0m * (1 - 19.44%))
Current Ratio = 1.56 (Total Current Assets 5.22b / Total Current Liabilities 3.34b)
Debt / Equity = 0.92 (Debt 2.52b / totalStockholderEquity, last quarter 2.73b)
Debt / EBITDA = 0.66 (Net Debt 685.3m / EBITDA 1.04b)
Debt / FCF = 0.65 (Net Debt 685.3m / FCF TTM 1.06b)
Total Stockholder Equity = 2.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.61% (Net Income 720.7m / Total Assets 7.50b)
RoE = 29.82% (Net Income TTM 720.7m / Total Stockholder Equity 2.42b)
RoCE = 16.99% (EBIT 621.0m / Capital Employed (Equity 2.42b + L.T.Debt 1.24b))
RoIC = 10.52% (NOPAT 500.3m / Invested Capital 4.76b)
WACC = 10.33% (E(22.83b)/V(25.35b) * Re(11.45%) + D(2.52b)/V(25.35b) * Rd(0.19%) * (1-Tc(0.19)))
Discount Rate = 11.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.03%
[DCF Debug] Terminal Value 71.17% ; FCFE base≈851.1m ; Y1≈1.05b ; Y5≈1.79b
Fair Price DCF = 45.50 (DCF Value 17.84b / Shares Outstanding 392.2m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 53.23 | EPS CAGR: 23.68% | SUE: 0.55 | # QB: 0
Revenue Correlation: 89.93 | Revenue CAGR: 15.42% | SUE: 1.47 | # QB: 3
Additional Sources for DXCM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle